Pharmaceutical Research and Manufacturers Association

Scypinski, S., Roberts, D., Oates, M., Etse, J. Pharmaceutical research and manufacturers association acceptable anbalytical practice for analytical method transfer. Pharm.Technol., 28, 2004, 84-88.2004... 

Pharmaceutical Research and Manufacturers of America. 2000. Pharmaceutical Industry Profile. Washington, DC Pharmaceutical Research and Manufacturing Association. 

Pharmaceutical Research and Manufacturers Association-Quick Facts (http // www.phrma. org/publications/quickfacts /14.08.2001.278.cfm). 

Pharmaceutical Research and Manufacturers Association of America (PhRMA) (1997, March), Microbiological monitoring of environmental conditions for nonsterile manufacturing, Pharm. Technol., 58-74. 

Pharmaceutical Research and Manufacturing Association (PhRMA). 2005. Intellectual Property Overview. Available at http //www.phrma.org/issues/intprop/ [Accessed April 10, 2005]. 

S. Scypinski, D. Roberts, M. Oates, and J. Etse, Pharmaceutical Research and Manufacturing Association acceptable analytical practice for analytical method transfer, Pharm. Technol. March (2002), 84—88. 

Survey. Medicines in Development. Biotechnology, Pharmaceutical Research and Manufacturers Association Washington, DC, Oct 2004. 

Holden A (2000) New medicines in development for women a 1999 survey. Pharmaceutical research and manufacturers association, www pharma. org/pdfwq pdf 29-36. 

The importance of analytical transfer was recently underscored by the Analytical Research and Development Steering Committee of the Pharmaceutical Research and Manufacturers Association (PhRMA) at their annual workshop. At this meeting, representatives from PhRMA member companies met with facilitators to draft an acceptable analytical practice (AAP) that will function as a suitable template for successful method transfer. Both facets of technology transfer have been discussed in this book. 

Pharmaceutical Research and Manufacturers Association Analytical Research and Development Workshop, Wilmington, DE, September 20, 2000. 

U.S. industry made for the same purpose. Next came the semiconductor and computer industries, which allocated 9.4 and 8.8% of sales proceeds to research. The all-industry average equaled a mere 3.7%. In 1996, each of 10 drug houses spent 1 biUion or more on research and development, amounts that represented 13-21% of sales income. The industry as a whole plans to spend 18.9 biUion for these purposes during 1997. This multibillion-doUar amount, according to the Pharmaceutical Research and Manufacturers Association, exceeds what about half of the state governments spend each year. It is nearly 12% higher than the 1996 investment. Marked by vast expenditures on innovative research, the recent past of the pharmaceutical industry justifies optimism, despite the turmoil created by consolidation. 

---